Skip to main content
Journal cover image

Endpoints in Heart Failure Drug Development: History and Future.

Publication ,  Journal Article
Fiuzat, M; Lowy, N; Stockbridge, N; Sbolli, M; Latta, F; Lindenfeld, J; Lewis, EF; Abraham, WT; Teerlink, J; Walsh, M; Heidenreich, P ...
Published in: JACC Heart Fail
June 2020

Heart failure (HF) patients experience a high burden of symptoms and functional limitations, and morbidity and mortality remain high despite successful therapies. The majority of HF drugs in the United States are approved for reducing hospitalization and mortality, while only a few have indications for improving quality of life, physical function, or symptoms. Patient-reported outcomes that directly measure patient's perception of health status (symptoms, physical function, or quality of life) are potentially approvable endpoints in drug development. This paper summarizes the history of endpoints used for HF drug approvals in the United States and reviews endpoints that measure symptoms, physical function, or quality of life in HF patients.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JACC Heart Fail

DOI

EISSN

2213-1787

Publication Date

June 2020

Volume

8

Issue

6

Start / End Page

429 / 440

Location

United States

Related Subject Headings

  • United States
  • Humans
  • History, 21st Century
  • History, 20th Century
  • Heart Failure
  • Health Status
  • Drug Development
  • Drug Approval
  • Cardiovascular Agents
  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Fiuzat, M., Lowy, N., Stockbridge, N., Sbolli, M., Latta, F., Lindenfeld, J., … McMurray, J. (2020). Endpoints in Heart Failure Drug Development: History and Future. JACC Heart Fail, 8(6), 429–440. https://doi.org/10.1016/j.jchf.2019.12.011
Fiuzat, Mona, Naomi Lowy, Norman Stockbridge, Marco Sbolli, Federica Latta, JoAnn Lindenfeld, Eldrin F. Lewis, et al. “Endpoints in Heart Failure Drug Development: History and Future.JACC Heart Fail 8, no. 6 (June 2020): 429–40. https://doi.org/10.1016/j.jchf.2019.12.011.
Fiuzat M, Lowy N, Stockbridge N, Sbolli M, Latta F, Lindenfeld J, et al. Endpoints in Heart Failure Drug Development: History and Future. JACC Heart Fail. 2020 Jun;8(6):429–40.
Fiuzat, Mona, et al. “Endpoints in Heart Failure Drug Development: History and Future.JACC Heart Fail, vol. 8, no. 6, June 2020, pp. 429–40. Pubmed, doi:10.1016/j.jchf.2019.12.011.
Fiuzat M, Lowy N, Stockbridge N, Sbolli M, Latta F, Lindenfeld J, Lewis EF, Abraham WT, Teerlink J, Walsh M, Heidenreich P, Bozkurt B, Starling RC, Solomon S, Felker GM, Butler J, Yancy C, Stevenson LW, O’Connor C, Unger E, Temple R, McMurray J. Endpoints in Heart Failure Drug Development: History and Future. JACC Heart Fail. 2020 Jun;8(6):429–440.
Journal cover image

Published In

JACC Heart Fail

DOI

EISSN

2213-1787

Publication Date

June 2020

Volume

8

Issue

6

Start / End Page

429 / 440

Location

United States

Related Subject Headings

  • United States
  • Humans
  • History, 21st Century
  • History, 20th Century
  • Heart Failure
  • Health Status
  • Drug Development
  • Drug Approval
  • Cardiovascular Agents
  • 3201 Cardiovascular medicine and haematology